Immune checkpoint inhibitor rechallenge in patients with immune-related myositis

Volume: 78, Issue: 11, Pages: e129 - e129
Published: Sep 21, 2018
Abstract
Therapeutic management of many cancers has been revolutionised by the development of immune checkpoint inhibitors (ICI) targeting antiprogrammed death 1 (PD-1)/ligand 1 (PDL1) and anticytotoxic T-lymphocyte antigen 4 leading to durable responses.1 ICIs however can induce several immune-related adverse events (irAE) including musculoskeletal irAEs.2 Among them, ICI-related myositis can be severe and sometimes life threatening.3 4 The current...
Paper Details
Title
Immune checkpoint inhibitor rechallenge in patients with immune-related myositis
Published Date
Sep 21, 2018
Volume
78
Issue
11
Pages
e129 - e129
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.